SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
141.60    -24.20 (-14.60%)
Bid:
140.20
Ask:
144.80
Spread: 4.60 (3.281%)
Market Cap: £241.94m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Trading Update

10 Jan 2019 07:00

RNS Number : 6695M
McBride PLC
10 January 2019
 

10 January 2019

 

McBride plc

 

Trading Update

 

McBride plc (the "Group"), the leading European manufacturer and supplier of Contract Manufactured and Private Label products for the domestic Household and professional cleaning and hygiene markets, today provides a trading update for the six months ended 31 December 2018.

 

The Group's first half continuing revenues at constant currency were 10.8% higher than the prior year. Excluding the benefit of first quarter revenues from Danlind, continuing underlying revenues were 6.0% higher. Underlying Household division sales were 5.9% higher, primarily as a result of higher sales in the East and UK regions (up 23.4% and 10.5% respectively).

 

As outlined in our recent AGM trading update, the first half year has seen raw material, packaging and logistics costs higher than anticipated, particularly in the second quarter. These have been partly mitigated by improved sales volumes and lower overheads. The pricing outlook for many of our key raw materials has improved recently and in the absence of this reversing significantly, the Board expects full year earnings to be in line with expectations, with full year profit delivery weighted to the second half.

The sale of the European Personal Care Liquids business was successfully completed during the second quarter and we continue to progress plans for the closure of our UK Aerosols factory in the second half year as expected. The integration of Danlind continued with our Danish factories transitioning onto the McBride ERP system in December.

 

The Group will announce its interim results for the six months ended 31 December 2018 on 21 February.

 

Rik De Vos, Chief Executive said;

 

"The Group has made significant strategic progress in the first half of this financial year completing the sale of Personal Care Liquids, integrating Danlind onto the McBride systems and managing our revenue growth. Margins remain our key focus at present and the recent improvement in the pricing outlook for raw materials following almost two years of significant inflation will see some recovery of the cumulative cost impact to the business. I remain confident that the Group continues to be well positioned to exploit the growth and margin opportunities in the remainder of this financial year and beyond."

 

 

For further information please contact:

 

McBride plc

Rik De Vos, Chief Executive Officer

0161 203 7570

Chris Smith, Chief Financial Officer

0161 203 7570

FTI Consulting

020 3727 1017

Ed Bridges, Nick Hasell

 

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016.

 

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTQKLFBKFFLBBV
Date   Source Headline
18th Nov 20259:42 amRNSHolding(s) in Company
31st Oct 20257:00 amRNSTotal Voting Rights
27th Oct 20257:00 amRNSHolding(s) in Company
23rd Oct 20256:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20257:00 amRNSApplication for Additional Listing of Shares
17th Oct 20256:23 pmRNSDirector/PDMR Shareholding
2nd Oct 20257:00 amRNSAnnual Financial Report
24th Sep 20257:00 amRNSRedemption of B Shares
19th Sep 20257:00 amRNSDirector/PDMR Shareholding
18th Sep 20259:04 amRNSEx-dividend date - Correction
17th Sep 20257:00 amRNSFinal Results
5th Sep 20257:00 amRNS-RInvestor Webinar on 18 September 2025
16th Jul 20257:00 amRNSFull Year Trading Update
16th Jun 20257:00 amRNSDirector/PDMR Shareholding
10th Jun 20257:00 amRNSHolding(s) in Company
29th May 20253:19 pmRNSHolding(s) in Company
23rd May 20251:42 pmRNSHolding(s) in Company
19th May 20257:00 amRNSHolding(s) in Company
12th May 20257:00 amRNSHolding(s) in Company
6th May 20257:00 amRNSHolding(s) in Company
29th Apr 20257:00 amRNSHolding(s) in Company
22nd Apr 20257:00 amRNSHolding(s) in Company
8th Apr 20257:00 amRNSHolding(s) in Company
28th Feb 20255:00 pmRNSHolding(s) in Company
25th Feb 20257:00 amRNSHalf-year Report
18th Feb 20256:15 pmRNSHolding(s) in Company
11th Feb 20254:40 pmRNSHolding(s) in Company
17th Jan 20257:00 amRNSTrading Statement
29th Nov 20247:00 amRNSSuccessful Completion of Refinancing
18th Nov 20241:10 pmRNSDirector/PDMR Shareholding
18th Nov 20241:09 pmRNSDirector/PDMR Shareholding
15th Nov 20241:10 pmRNSDirector/PDMR Shareholding
12th Nov 20246:36 pmRNSResult of Annual General Meeting
12th Nov 20247:00 amRNSAGM Trading Update
6th Nov 20243:53 pmRNSDirector/PDMR Shareholding
31st Oct 20247:00 amRNSDirector/PDMR Shareholding
25th Oct 20243:48 pmRNSDirector/PDMR Shareholding
8th Oct 20246:25 pmRNSDirector/PDMR Shareholding
7th Oct 20247:00 amRNSAnnual Financial Report
1st Oct 20245:30 pmRNSDirector/PDMR Shareholding
26th Sep 20247:00 amRNSDirector/PDMR Shareholding
24th Sep 20243:38 pmRNSDirector/PDMR Shareholding
20th Sep 20245:17 pmRNSDirector/PDMR Shareholding
19th Sep 20247:00 amRNSDirector/PDMR Shareholding
17th Sep 20247:00 amRNSFinal Results
16th Jul 20247:00 amRNSFull Year Trading Update
3rd Jul 20242:33 pmRNSHolding(s) in Company
14th Jun 20247:00 amRNSGrant and vesting of RSU Awards to PDMR
2nd May 20249:21 amRNSHolding(s) in Company
30th Apr 20247:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.